Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1996 to 2010 of 8218 results

  1. Epilepsies in children, young people and adults

    In development Reference number: GID-NG10453 Expected publication date: TBC

    NICE guideline
    In development

  2. Retatrutide for managing overweight and obesity [ID6644]

    Awaiting development Reference number: GID-TA11845 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Digital flexor tenotomy for diabetic foot

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development Reference number: GID-TA10911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years [ID6554]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. DCVax-L for treating glioblastoma [ID836]

    In development Reference number: GID-TA10143 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]

    Awaiting development Reference number: GID-TA11761 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date:  18 March 2026

    Technology appraisal guidance
    In development

  13. Dermal allograft augmentation in proximal humerus fracture fixation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]

    Awaiting development Reference number: GID-TA11858 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development